A Phase 3 interventional study of rhPSMA-7.3 (18F) Injection and Positron emission tomography scan in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 28 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one has the largest enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
University of Florida · Sites in United States
Ages 18–100 · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18–90 · Men only
Hackensack Meridian Health · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2019; this study’s year is marked. 2 started in 2020.
This study's enrollment of 391 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 70 across the 15 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
13 studies in Prostatic Neoplasms by Bracco: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Prostatic Neoplasms by Bracco, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
Bracco’s Prostatic Neoplasms studies by the year they started, since 2009.
1 of the studies testing flotufolastat F 18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285057Icahn School of Medicine at Mount SinaiDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, from their registry updates:
Among Bracco’s 13 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.
The primary objective of this study was to assess the patient-level correct detection rate (CDR) and region-level positive predictive value (PPV) of rhPSMA-7.3 (18F) positron emission tomography (PET) for biochemical recurrence (BCR) of prostate cancer using histopathology or imaging as a standard of truth (SoT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An elevated PSA, clinically suspicious for biochemically recurrent disease:
Exclusion Criteria:
Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Drug: rhPSMA-7.3 (18F) Injection · Diagnostic Test: Positron emission tomography scan
Radioligand for PET CT scanning
Also known as: flotufolastat F18
Imaging scan with radioligand
Also known as: PET scan
Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT
The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET in Patients Who Had Negative Baseline Conventional Imaging
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Patient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
CDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Percentage of Patients in Whom rhPSMA-7.3 (18F) PET Imaging Results Changed the Intended Patient Management (Major and Other Changes)
This analysis used patients in the EAP who had documented patient management plans in the EDC before and after the rhPSMA-7.3 (18F) PET scan
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reader Kappa Statistics of rhPSMA7.3 (18F) Scan Interpretation by the Blinded Independent Readers
The Cohen's kappa statistic will be calculated to assess pairwise agreement between any 2 blinded independent readers
Time frame: PET Scan on Day 1
Region-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level
Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available
Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions. The data are analysed by whether the patients have had histopathology as reference standard.
Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
This study was conducted from 04 May 20 (first patient, screening visit) and 12 Oct 21 (database lock), with last patient, last visit on 28 Apr 21. It was conducted at 28 activated study sites (27 recruited) in 3 countries. Of the 420 patients screened, 391 patients met all the study eligibility criteria
| Milestone | Single Arm |
|---|---|
| Started | 391 |
| Completed | 378 |
| Not completed | 13 |
| Withdrew: Death | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Biopsy ordered but area too small to biopsy | 1 |
| Withdrew: Biopsy ordered but not done | 1 |
| Withdrew: It was previously confirmed | 1 |
| Withdrew: Patient cancelled scheduled scans | 2 |
| Withdrew: Psma pet/ct scan show disease within previously bx area | 1 |
| Withdrew: Subject refused confirmatory imaging | 1 |
| Withdrew: Too small to biopsy | 1 |
The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.
| percentage | Efficacy Analysis Population (EAP) |
|---|---|
| Patient-level CDR - Central Reader 1 | 54.1 (48.8 to 59.3) |
| Patient-level CDR - Central Reader 2 | 51.4 (46.1 to 56.6) |
| Patient-level CDR - Central Reader 3 | 51.6 (46.4 to 56.9) |
| Region-level PPV - Central Reader 1 | 46.2 (42.0 to 50.3) |
| Region-level PPV - Central Reader 2 | 60.3 (55.1 to 65.5) |
| Region-level PPV - Central Reader 3 | 52.6 (47.6 to 57.5) |
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.
| percentage | Efficacy Analysis Population (EAP) |
|---|---|
| Patient Level CDR - Central Reader 1 | 46.8 (40.5 to 53.2) |
| Patient Level CDR - Central Reader 2 | 45.2 (38.9 to 51.6) |
| Patient Level CDR - Central Reader 3 | 45.6 (39.3 to 52.0) |
| Region-level PPV - Central Reader 1 | 39.7 (34.6 to 44.9) |
| Region-level PPV - Central Reader 2 | 56.2 (49.6 to 62.7) |
| Region-level PPV - Central Reader 3 | 46.8 (40.7 to 52.9) |
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.
| percentage | Histopathology Available as SoT | Histopathology Not Available as SoT |
|---|---|---|
| Patient-level CDR - Central Reader 1 | 75.4 (63.5 to 84.9) | 49.2 (43.3 to 55.0) |
| Patient-level CDR - Central Reader 2 | 76.8 (65.1 to 86.1) | 45.5 (39.7 to 51.3) |
| Patient-level CDR - Central Reader 3 | 73.9 (61.9 to 89.7) | 46.5 (40.7 to 52.3) |
| Region-level PPV - Central Reader 1 | 60.9 (52.0 to 69.8) | 42.4 (37.7 to 47.0) |
| Region-level PPV - Central Reader 2 | 67.0 (57.6 to 76.4) | 57.9 (51.7 to 64.0) |
| Region-level PPV - Central Reader 3 | 62.6 (53.5 to 71.8) | 49.5 (43.8 to 55.3) |
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients
| percentage | PSA<0.5 | 0.5≤PSA<1.0 | 1.0≤PSA<2.0 | 2.0≤PSA<5.0 | 5.0≤PSA<10.0 | PSA≥10.0 |
|---|---|---|---|---|---|---|
| Central Reader 1 | 29.5 (21.0 to 39.2) | 44.4 (31.9 to 57.5) | 65.1 (49.1 to 79.0) | 72.7 (62.2 to 81.7) | 61.1 (43.5 to 76.9) | 80.7 (62.5 to 92.5) |
| Central Reader 2 | 23.8 (16.0 to 33.1) | 41.3 (29.0 to 54.4) | 65.1 (49.1 to 79.0) | 70.5 (59.8 to 79.7) | 58.3 (40.8 to 74.5) | 83.9 (66.3 to 94.5) |
| Central Reader 3 | 25.7 (17.7 to 35.2) | 46.0 (33.4 to 59.1) | 62.8 (46.7 to 77.0) | 69.3 (58.6 to 78.7) | 58.3 (40.8 to 74.5) | 77.4 (58.9 to 90.4) |
Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers
| percentage | Prostate/ Prostate Bed | Pelvic Lymph Nodes | Other (Extra-pelvic) Sites |
|---|---|---|---|
| Central Reader 1 | 16.7 (13.0 to 20.9) | 21.6 (17.5 to 26.2) | 29.2 (24.6 to 34.2) |
| Central Reader 2 | 13.1 (9.8 to 17.0) | 19.4 (15.5 to 23.8) | 30.6 (25.9 to 35.6) |
| Central Reader 3 | 13.7 (10.3 to 17.6) | 22.4 (18.2 to 27.0) | 25.7 (21.3 to 30.5) |
This analysis used patients in the EAP who had documented patient management plans in the EDC before and after the rhPSMA-7.3 (18F) PET scan
| percentage | Change in Management Plan |
|---|---|
| No Change | 6.6 |
| Major Change | 46.7 |
| Minor Change | 4.8 |
| Additional Information Required | 31.7 |
| Pre-PSMA Plan Not Valid | 10.2 |
The Cohen's kappa statistic will be calculated to assess pairwise agreement between any 2 blinded independent readers
| percentage | Patient-level Inter-reader Reproducibility |
|---|---|
| Central Reader 1 vs Reader 2 | 0.29 (0.21 to 0.38) |
| Central Reader 1 vs Reader 3 | 0.38 (0.25 to 0.51) |
| Central Reader 2 vs Reader 3 | 0.50 (0.41 to 0.60) |
Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.
| percentage | PSA <0.5 | 0.5≤PSA<1.0 | 1.0≤PSA<2.0 | 2.0≤PSA<5.0 | 5.0≤PSA<10.0 | PSA≥10.0 |
|---|---|---|---|---|---|---|
| Central Reader 1 | 29.1 (20.5 to 37.7) | 37.1 (27.6 to 46.6) | 45.6 (35.1 to 56.1) | 57.7 (50.1 to 65.3) | 57.9 (44.9 to 70.9) | 59.6 (47.6 to 71.7) |
| Central Reader 2 | 50.8 (36.9 to 64.8) | 51.8 (38.9 to 64.6) | 57.4 (43.7 to 71.1) | 65.0 (55.3 to 74.6) | 71.7 (56.8 to 86.7) | 62.7 (50.6 to 74.9) |
| Central Reader 3 | 34.5 (24.0 to 45.0) | 45.1 (33.5 to 56.7) | 52.5 (38.7 to 66.2) | 64.9 (55.9 to 73.9) | 58.7 (41.5 to 75.9) | 60.8 (47.3 to 74.2) |
Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions. The data are analysed by whether the patients have had histopathology as reference standard.
| percentage | Histopathology Available as SoT | Histopathology Not Available as SoT |
|---|---|---|
| Central Reader 1 | 60.9 (52.0 to 69.8) | 42.4 (37.7 to 47.0) |
| Central Reader 2 | 67.0 (57.6 to 76.4) | 57.9 (51.7 to 64.0) |
| Central Reader 3 | 62.6 (53.5 to 71.8) | 49.5 (43.8 to 55.3) |
Collected over AEs were also monitored throughout the study through study completion, an average of 90 days post-IMP administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm | 2/391 (0.5%) | 2/391 (0.5%) | 28/391 (7.2%) |
| Event | Single Arm |
|---|---|
| Sudden deathGeneral disorders | 1/391 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/391 |
| Event | Single Arm |
|---|---|
| HypertensionVascular disorders | 7/391 |
| DiarrheaGastrointestinal disorders | 4/391 |
| Injection site reactionGeneral disorders | 2/391 |
| HeadacheNervous system disorders | 2/391 |
| FlushingVascular disorders | 1/391 |
| Injection site discomfortGeneral disorders | 1/391 |
| FatigueGeneral disorders | 1/391 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 1/391 |
| AnxietyPsychiatric disorders | 1/391 |
| TachycardiaCardiac disorders | 1/391 |
All patients who were scheduled to receive the rhPSMA-7.3 (18F) injection having met the inclusion/exclusion criteria or who received the rhPSMA-7.3 (18F) injection.
| Age, Categorical(Participants) | Single Arm |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 121 |
| >=65 years | 270 |
| Age, Continuous(years) | Single Arm |
|---|---|
| Mean | 68.3 ± 7.92 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 0 |
| Male | 391 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 342 |
| Unknown or Not Reported | 31 |
| Race/Ethnicity, Customized(participants) | Single Arm |
|---|---|
| Black or African American | 61 |
| White | 295 |
| Other | 14 |
| Not Reported | 21 |
| Region of Enrollment(participants) | Single Arm |
|---|---|
| Netherlands | 9 |
| United States | 375 |
| Finland | 7 |
| Total Gleason Score(participants) | Single Arm |
|---|---|
| ≤6 | 39 |
| =7 | 232 |
| =8 | 41 |
| =9 | 63 |
| =10 | 1 |
| Missing | 15 |
| Gleason Grade Group (GGG)(participants) | Single Arm |
|---|---|
| =1 | 39 |
| =2 | 104 |
| =3 | 116 |
| =4 | 41 |
| =5 | 64 |
| Missing | 27 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Apr 2021, 11 months.
Results were first posted in Feb 2025, 3 years 9 months after primary completion. A results delay was requested in Mar 2022.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 11 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flotufolastat F 18